Order NUVAXOVID and Access Resources

NUVAXOVID is approved for use in anyone who is 65 years of age and older. It is also approved for use in people aged 12 through 64 who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.¹

 

Risk of severe COVID-19 outcomes is increased among adults with underlying medical conditions. Examples include:

• COPD
• Chronic kidney disease
• Chronic liver disease
• Cerebrovascular disease, including stroke
• Heart failure and heart conditions
• Mental health conditions, including depression
• Physical inactivity
• Dementia
• Substance use disorders
• Obesity

The complete and most up-to-date list is available on the CDC website.

 

To be eligible for NUVAXOVID, a patient must be either over the age of 65 or between the ages of 12 and 64 with at least one underlying condition putting them at risk of more severe outcomes of COVID-19.¹
 
If a patient falls between 12 and 64 years of age but does not know if they have an eligible underlying condition, you can ask them for a brief medical history or refer them to the up-to-date list of conditions on the CDC website.²

 

[XFG is the scientifically optimal strain for the 2026–2027 COVID-19 vaccine. It has been the dominant circulating variant globally for more than six months, with no other variant achieving consistent global dominance during this period. Sanofi has committed to manufacturing NUVAXOVID^TM (COVID-19 Vaccine, Adjuvanted) to help prevent COVID-19 caused by the XFG strain and its descendant sub-lineages for the upcoming vaccination season and is on track to deliver a timely supply.³]

 

NUVAXOVID is a recombinant protein-based, non-mRNA vaccine. Recombinant technology directly provides the antigen protein needed for antibody protection. The recombinant spike protein is developed using technology already present in certain modern flu vaccines. Protein-based vaccines work differently from mRNA vaccines. mRNA vaccines instruct our cells to make a protein like the one in the virus—then our immune system can learn to recognize it as a target.^1,4,5
 
NUVAXOVID is also adjuvanted, using naturally-derived Matrix-M (Quillaja saponaria Molina) to provide a robust and enhanced immune response.^1,4,6
 
It comes ready to use, with no dilution, mixing, or thawing required, and it can be stored in a standard refrigerator between 2 to 8 °C (36 to 46 °F).¹
 
The vaccine offers low reactogenicity with minimal disruptive side effects.¹ In clinical trials, the majority of side effects were mild to moderate and would not prevent daily activities, according to FDA grading.^1,7,8

 

The Matrix-M adjuvant is included to help provide a robust and enhanced immune profile. It is a saponin-based adjuvant made from purified saponin from the bark of the South American soapbark tree Quillaja saponaria Molina with cholesterol and phospholipid. In clinical trials, the use of Matrix-M has been reported as well tolerated. In the clinical program, no episodes of anaphylaxis were observed.^6,9

 

Yes, according to the CDC, COVID-19 and flu vaccines can be administered at the same appointment.¹⁰

 

NUVAXOVID is the same vaccine that was previously manufactured by NOVAVAX. It’s now manufactured by Sanofi and updated to match this season’s COVID-19 strain.

 

NUVAXOVID is administered as a single dose in patients not previously vaccinated with any COVID-19 vaccine, or in those who have, as a single seasonal dose at least 2 months following any prior COVID-19 vaccine.^1,5

For patients 65 and older and patients who are moderately to severely immunocompromised, ACIP recommends an additional dose 2-6 months later.¹⁰